Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
4(50%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_2
3
38%
Ph phase_4
5
63%

Phase Distribution

0

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
3(37.5%)
Phase 4Post-market surveillance
5(62.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(4)

Detailed Status

Completed4
Active, not recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (37.5%)
Phase 45 (62.5%)

Trials by Status

active_not_recruiting225%
completed450%
recruiting225%

Recent Activity

4 active trials
Showing 5 of 8
recruitingphase_2

CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

NCT03769298
recruitingphase_2

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

NCT03321656
completedphase_4

Envarsus XR Compared to Immediate Release Tacrolimus

NCT03979365
active_not_recruitingphase_4

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

NCT04665310
completedphase_4

Envarsus in Delayed Graft Function (E-DGF)

NCT03864926
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03769298Phase 2

CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

Recruiting
NCT03321656Phase 2

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

Recruiting
NCT03979365Phase 4

Envarsus XR Compared to Immediate Release Tacrolimus

Completed
NCT04665310Phase 4

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Active Not Recruiting
NCT03864926Phase 4

Envarsus in Delayed Graft Function (E-DGF)

Completed
NCT03266393Phase 4

Envarsus XR® in Adolescent Renal Transplant Recipients

Active Not Recruiting
NCT03270462Phase 4

CNS Study of Patients Switching From Tacrolimus to Envarsus

Completed
NCT03828058Phase 2

Envarsus XL Immunosuppression Following Liver Transplantation

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8